Status:
COMPLETED
An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This prospective, observational study will assess the effect of RoActemra/Actemra (tocilizumab) on fatigue in patients with moderate to severe rheumatoid arthritis who have an inadequate response to d...
Eligibility Criteria
Inclusion
- Adult patients, \>/= 18 years of age
- Moderate to severe rheumatoid arthritis
- Inadequate response to disease-modifying antirheumatic drugs (DMARDS) or anti-TNF (tumor necrosis factor) drugs
Exclusion
- Hypersensitivity to RoActemra/Actemra or any component
- Active infection
- Participation in a clinical trial in rheumatoid arthritis
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
719 Patients enrolled
Trial Details
Trial ID
NCT01185522
Start Date
January 1 2010
End Date
May 1 2011
Last Update
June 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuilly-sur-Seine, France, 92521